Goettingen, Germany 6/28/16; Albuquerque, NM 6/28/16—Pharmaceutical and lab equipment supplier Sartorius has acquired IntelliCyt for $90 million in cash, including $5 million in future tax savings. Based in Albuquerque, New Mexico, with 55 employees, IntelliCyt provides cell screening platforms for drug discovery applications. IntelliCyt’s revenues are expected to increase approximately 34% in 2016 to more than $18 million. The company is expected to breakeven on underlying EBITDA by the end of 2017. “Novel cell screening methods are crucial to enable scientific progress in the fast expanding research areas of immuno-oncology, antibody discovery and immune targets,” stated Sartorius CEO Joachim Kreuzburg. “IntelliCyt has developed a powerful platform that integrates instruments, reagents and software seamlessly across the workflow.”

This is Sartorius’s first cell-based analysis instrumentation acquisition, as the company has previously focused on more routine laboratory products, such as pipettes and balances, as well as bioprocessing products. IntelliCyt’s iQue instruments provide multiplexed, high-throughput suspension cell- and bead-based assay screening in a flow format.